Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
Andrea Chiricozzi, Niccolò Gori, Alessandra Narcisi, et al.
Drugs in R&D (2022) Vol. 22, Iss. 3, pp. 245-252
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
Masahiro Kamata, Yayoi Tada
JID Innovations (2023) Vol. 3, Iss. 3, pp. 100195-100195
Open Access | Times Cited: 43
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 919-932
Open Access | Times Cited: 19
Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report
Katrina Cirone, Fiona Lovegrove
SAGE Open Medical Case Reports (2025) Vol. 13
Open Access | Times Cited: 2
Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
Luigi Gargiulo, Luciano Ibba, Giulia Pavia, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 26
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation
Andrea Chiricozzi, Michela Ortoncelli, Donatella Schena, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 6, pp. 953-961
Open Access | Times Cited: 25
Successful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study
Stamatios Gregoriou, Ioannis‐Alexios Koumprentziotis, Ileana Afroditi Kleidona, et al.
Dermatology and Therapy (2025)
Open Access | Times Cited: 1
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study
Luigi Gargiulo, Luciano Ibba, Andrea Cortese, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 2, pp. 651-660
Open Access | Times Cited: 22
Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults
Axel De Greef, Pierre‐Dominique Ghislain, Laurence de Montjoye, et al.
Advances in Therapy (2023) Vol. 40, Iss. 5, pp. 2509-2514
Open Access | Times Cited: 22
Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis
C. Ertus, Lucie‐Marie Scailteux, Alain Lescoat, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 4, pp. 368-380
Closed Access | Times Cited: 18
Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: A multicenter retrospective study
Andrea Chiricozzi, Anna Balato, Gabriella Fabbrocini, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 6, pp. 1251-1253
Closed Access | Times Cited: 17
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study
Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 2
Open Access | Times Cited: 17
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
Luciano Ibba, Luigi Gargiulo, Carlo Alberto Vignoli, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 593-604
Open Access | Times Cited: 8
Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry
Esmé Kamphuis, Laura Loman, H. Han, et al.
Contact Dermatitis (2023) Vol. 88, Iss. 5, pp. 351-362
Open Access | Times Cited: 15
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
Celeste M. Boesjes, Lian F. van der Gang, Nicolaas P. A. Zuithoff, et al.
Acta Dermato Venereologica (2023) Vol. 103, pp. adv00872-adv00872
Open Access | Times Cited: 13
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis
Elena Pezzolo, Michela Ortoncelli, Silvia Ferrucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 553-553
Open Access | Times Cited: 5
Upadacitinib for Moderate to Severe Atopic Dermatitis
F.J. Navarro‐Triviño, Sara Alcantara‐Luna, J.J. Domínguez-Cruz, et al.
Immunotherapy (2023) Vol. 15, Iss. 11, pp. 799-808
Closed Access | Times Cited: 11
Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
Francisco Javier Melgosa Ramos, Carlos Abril‐Pérez, Santiago Guillén‐Climent, et al.
Anais Brasileiros de Dermatologia (2025)
Open Access
Efficacy and Treatment Satisfaction of Different Systemic Therapies in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study
Sebastian Kiefer, Anke König, Viviane Gerger, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 1175-1175
Open Access | Times Cited: 10
Upadacitinib effectiveness in moderate‐to‐severe atopic dermatitis: A real‐life multicentre and retrospective study
Francisco Javier Melgosa Ramos, V.A. González-Delgado, José María Sánchez Motilla, et al.
Australasian Journal of Dermatology (2023) Vol. 64, Iss. 4
Closed Access | Times Cited: 8
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial
Carsten Flohr, Michael J. Cork, Michael R. Ardern‐Jones, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 7
Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system
Xiangping Wu, Xikui Lu, Zhenting Wang, et al.
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 10, pp. 975-984
Closed Access | Times Cited: 7
Upadacitinib treatment in a real‐world difficult‐to‐treat atopic dermatitis patient cohort
Anne R. Schlösser, Neill Boeijink, Jill I. Olydam, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 2, pp. 384-392
Open Access | Times Cited: 7
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study
Virginia Solitano, Paola Facheris, Magnus Petersen, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 3, pp. 103504-103504
Open Access | Times Cited: 7
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment
Niccolò Gori, Elena Ippoliti, Flaminia Antonelli, et al.
Clinical and Experimental Dermatology (2023) Vol. 48, Iss. 5, pp. 558-559
Open Access | Times Cited: 6
Real-world Experience With Upadacitinib in Adolescents and Adults With Refractory Atopic Dermatitis: A 24-week Retrospective Study
J. Naharro-Rodríguez, Emilio Berná-Rico, F.J. Pérez-Bootello, et al.
Actas Dermo-Sifiliográficas (2024) Vol. 115, Iss. 6, pp. 615-617
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top